ACADIA Pharmaceuticals Inc.(ACAD)Earnings, Financials & Key RatiosACADIA Pharmaceuticals Inc. (ACAD) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the balance sheet is healthy with $851.5 million in cash, the deceleration in revenue growth to 9.7% and inconsistent cash conversion warrant a cautious wait-and-see approach.
ACADIA Pharmaceuticals Inc. (ACAD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
ACADIA Pharmaceuticals Inc. (ACAD) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.02vs $0.04-50.0% | $268Mvs $280M-4.3% |
| Q1 2026 | Feb 25, 2026 | $1.60vs $0.14+1067.9% | $284Mvs $293M-3.0% |
| Q4 2025 | Nov 5, 2025 | $0.26vs $0.14+85.7% | $279Mvs $293M-4.8% |
| Q3 2025 | Aug 6, 2025 | $0.16vs $0.14+14.3% | $265Mvs $262M+1.0% |
Recent stock market news and headlines for ACADIA Pharmaceuticals Inc. (ACAD)
Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.
Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europe. Remlifanserin's upcoming phase 2 readout in Alzheimer's disease psychosis is a high-risk, high-reward catalyst not priced into ACAD's current valuation. I maintain a bullish outlook on ACAD based on commercial products Nuplazid and Daybue, but above-average returns depend on pipeline or business development success.
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares are trading higher on Friday as the company is celebrating a positive recommendation from the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) regarding its drug DAYBU (trofinetide) for treating neurobehavioral symptoms of Rett syndrome in the European Union.
Acadia Pharmaceuticals focuses on underserved rare diseases. Although they're (by definition) small markets, there's often little to no competition to treat rare and underserved diseases.
Key metrics vs top competitors for ACADIA Pharmaceuticals Inc. (ACAD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $26.20 | $4.49B | 11.44 | 11.87% | 36.49% | 39.89% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $249.76 | $12.85B | -67.87 | 65.55% | -26.59% | -260.01% | — | |
| $5.59 | $2.47B | 9.90 | 50.54% | 8.99% | 14.24% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — | |
| $205.70 | $30.37B | 23.30 | 1.39% | 13.92% | 7.55% | — |
ACADIA Pharmaceuticals Inc. (ACAD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACADIA Pharmaceuticals Inc. (ACAD) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 6, 2026·SEC
Mar 5, 2026·SEC
Feb 25, 2026·SEC
Get notified when ACAD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACADIA Pharmaceuticals Inc. (ACAD) stock FAQ — growth, dividends, profitability & financials explained
ACADIA Pharmaceuticals Inc. (ACAD) reported $1.10B in revenue for fiscal year 2025. This represents a 25300% increase from $4.3M in 2000.
ACADIA Pharmaceuticals Inc. (ACAD) grew revenue by 11.9% over the past year. This is steady growth.
Yes, ACADIA Pharmaceuticals Inc. (ACAD) is profitable, generating $375.6M in net income for fiscal year 2025 (36.5% net margin).
ACADIA Pharmaceuticals Inc. (ACAD) has a return on equity (ROE) of 39.9%. This is excellent, indicating efficient use of shareholder capital.
ACADIA Pharmaceuticals Inc. (ACAD) generated $212.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
